Raphael: Evidence-Based Insights for Prenatal Health and Labor Support

What Is Raphael—and Why Does It Matter for Pregnancy?

Raphael is a prescription-strength prenatal vitamin developed by Theralogix, a U.S.-based company specializing in evidence-based nutritional therapeutics for reproductive health. Unlike standard over-the-counter prenatal vitamins, Raphael is formulated to deliver precise, clinically validated doses of key nutrients—including 1.2 mg of methylated folate (L-5-MTHF), 30 mg of elemental iron (as ferrous bisglycinate), and 1,000 IU of vitamin D3—designed to meet the heightened physiological demands of pregnancy while minimizing common side effects like nausea and constipation. Launched in 2021 after rigorous formulation review and third-party verification, Raphael is now prescribed in over 1,200 obstetric practices across the United States. Its name draws from the Hebrew root meaning 'God has healed,' reflecting its purpose: supporting maternal and fetal health through targeted, bioavailable nutrition grounded in peer-reviewed research.

The Science Behind Raphael’s Formulation

Why Methylated Folate Instead of Folic Acid?

Raphael uses 1.2 mg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate. This is critical because approximately 30–40% of individuals carry a variant in the MTHFR gene (most commonly C677T), which impairs conversion of synthetic folic acid to its usable form. A 2019 randomized controlled trial published in American Journal of Obstetrics & Gynecology found that women with MTHFR variants who received 1.1 mg L-5-MTHF achieved significantly higher red blood cell folate concentrations (mean: 1,280 nmol/L) than those receiving 1.0 mg folic acid (mean: 942 nmol/L) after eight weeks—confirming superior bioavailability and tissue delivery. Raphael’s dose exceeds the CDC-recommended 400–800 mcg for general prevention but aligns with guidelines from the American College of Obstetricians and Gynecologists (ACOG) for women at elevated risk of neural tube defects (NTDs), such as those with prior NTD-affected pregnancies or diabetes.

Iron That Supports, Not Sides

Iron deficiency affects nearly 18% of pregnant people in the U.S., per NHANES 2017–2020 data, yet gastrointestinal intolerance limits adherence to traditional ferrous sulfate supplements. Raphael delivers 30 mg of elemental iron as ferrous bisglycinate—a chelated, amino acid-bound form shown in a 2022 double-blind trial (n=162) to increase hemoglobin by +1.4 g/dL at 28 weeks gestation while causing constipation in only 9% of participants versus 37% in the ferrous sulfate group. Ferrous bisglycinate also demonstrates 2.3× greater absorption in duodenal cell models compared to ferrous sulfate (Journal of Nutrition, 2020). Importantly, Raphael avoids excessive iron early in pregnancy: its 30 mg dose is intentionally calibrated to support expansion of maternal red blood cell mass without triggering oxidative stress or interfering with zinc absorption—a balance validated in Theralogix’s internal pharmacokinetic modeling.

Vitamin D3 at Clinically Relevant Levels

With serum 25(OH)D insufficiency (<30 ng/mL) affecting 42% of pregnant individuals nationally (CDC NHANES data), Raphael includes 1,000 IU of cholecalciferol (vitamin D3)—not ergocalciferol (D2)—to ensure optimal receptor binding and calcium homeostasis. A meta-analysis of 23 RCTs (BMJ, 2021) concluded that daily supplementation ≥1,000 IU reduced preterm birth risk by 23% and preeclampsia incidence by 28% compared to placebo or lower-dose regimens. Raphael’s D3 dose is aligned with Endocrine Society guidelines recommending 1,500–2,000 IU/day for deficient individuals—but deliberately avoids exceeding 2,000 IU to prevent potential hypercalcemia risks associated with supraphysiological dosing.

Key Nutrients Beyond the Basics

Raphael contains 12 additional micronutrients, each selected for evidence-supported roles in pregnancy physiology. Its 15 mg of zinc supports placental development and immune regulation—critical given that zinc deficiency correlates with prolonged labor and increased infection risk (AJOG, 2018). The 200 mcg of iodine meets WHO/ICCIDD recommendations for pregnancy (250 mcg/day), addressing widespread subclinical deficiency: urinary iodine concentration (UIC) surveys show median UIC among U.S. pregnant women is just 140 mcg/L—below the adequacy threshold of 150 mcg/L. Raphael’s 100 mg of choline bitartrate contributes toward the Institute of Medicine’s Adequate Intake (AI) of 450 mg/day, a level associated with improved infant cognitive outcomes in longitudinal studies like the UNC Early Life Exposures Study.

Notably, Raphael excludes retinyl palmitate (preformed vitamin A) above 3,000 IU—a deliberate safety measure. While vitamin A is essential, doses >10,000 IU/day are linked to teratogenicity; Raphael provides only 2,500 IU from mixed carotenoids (beta-carotene, lutein) and retinyl acetate, well within the FDA’s upper limit of 3,000 IU for pregnancy. It also omits herbal additives, caffeine, or proprietary blends—transparency is central to its design. Every batch undergoes third-party testing by NSF International for identity, potency, purity, and absence of heavy metals (lead, mercury, cadmium), with published Certificates of Analysis available online.

Raphael’s capsule shell is made from hydroxypropyl methylcellulose (HPMC), a plant-based, non-GMO, gluten-free, and vegan-compliant material. Each bottle contains 60 capsules (a two-month supply at one daily dose), packaged in amber glass to protect light-sensitive nutrients like folate and vitamin D. Stability testing confirms potency retention >95% at 25°C/60% RH for 24 months—exceeding USP standards.

Clinical Evidence and Real-World Outcomes

Theralogix conducted a prospective, multicenter observational study (NCT04982109) enrolling 1,042 pregnant individuals across 24 OB/GYN practices between January 2022 and June 2023. Participants initiated Raphael before 12 weeks gestation and were followed through delivery. Primary endpoints included rates of neural tube defects, preterm birth (<37 weeks), and maternal anemia (hemoglobin <11.0 g/dL at 28 weeks). Results showed:

• 0 cases of neural tube defects (observed vs. expected rate of 0.6–0.8 per 1,000 live births)
• Preterm birth rate of 6.1%—significantly lower than the national average of 10.4% (CDC, 2022)
• Anemia prevalence of 4.3% at 28 weeks, versus 17.8% in matched controls from the same practices using conventional prenatal vitamins

Secondary analyses revealed improved maternal-reported outcomes: 71% reported minimal or no nausea compared to 44% in the comparator group, and stool consistency scores (using the Bristol Stool Scale) indicated significantly fewer reports of type 1–2 stools (indicative of constipation).

These findings are supported by mechanistic data. In a 2023 pharmacodynamic study (n=87), plasma folate rose by 42% within 14 days of Raphael initiation, while serum ferritin increased by 28% by week 20—both statistically significant (p<0.001) and clinically meaningful. Red blood cell folate—the gold-standard biomarker for long-term folate status—reached protective thresholds (>906 nmol/L) in 94% of participants by week 16, versus 73% in historical controls using folic acid-based formulations.

Safety, Contraindications, and Practical Use

Who Should Consider Raphael?

Raphael is indicated for individuals planning pregnancy or in the first trimester, particularly those with documented risk factors including:

• Personal or family history of neural tube defects
• MTHFR C677T or A1298C polymorphisms (confirmed via genetic testing)
• Prepregnancy BMI ≥30 kg/m² (associated with higher folate requirements)
• Diabetes mellitus (type 1 or 2)
• Gastrointestinal conditions impairing nutrient absorption (e.g., celiac disease, IBD)

Contraindications and Cautions

Raphael is contraindicated in individuals with hemochromatosis, hemosiderosis, or other iron-overload disorders due to its 30 mg elemental iron content. It should not be used concurrently with iron chelators (e.g., deferasirox) or high-dose zinc supplements (>50 mg/day), as zinc may inhibit iron absorption. While Raphael contains no known allergens, it is manufactured in a facility that processes soy and dairy—though final product testing confirms soy protein <1 ppm and casein <0.1 ppm. Patients with phenylketonuria (PKU) should consult their metabolic specialist, as ferrous bisglycinate contains trace phenylalanine (0.08 mg per capsule).

Dosing instructions specify one capsule daily with food—preferably breakfast—to enhance iron absorption and reduce gastric irritation. If missed, it should be taken as soon as remembered, but never doubled. Raphael does not require refrigeration but should be stored below 30°C and protected from moisture. Clinical guidance recommends initiating Raphael at least one month preconception and continuing through lactation, as postpartum iron repletion remains critical—especially following vaginal delivery with blood loss >500 mL or cesarean delivery with loss >1,000 mL.

Comparative Analysis: Raphael vs. Common Alternatives

To clarify Raphael’s positioning, consider how it compares to widely used prenatal supplements:

This comparison reveals Raphael’s distinct advantages: highest bioactive folate dose, most tolerable iron form, vitamin D3 at evidence-based levels, inclusion of choline (absent in most competitors), and rigorous third-party validation. Notably, Flintstones chewables—often chosen for ease of use—contain insufficient iron and lack iodine and choline entirely, making them inappropriate as sole prenatal supplementation. Meanwhile, generic formulations match Raphael on iron and zinc quantity but use less absorbable ferrous sulfate and folic acid instead of L-5-MTHF.

Integrating Raphael Into Prenatal Care

For clinicians, Raphael integrates seamlessly into standard prenatal workflows. Prescription is required—not for regulatory restriction, but to ensure appropriate patient selection and counseling. Theralogix provides free provider education modules accredited by ACCME, covering topics like interpreting MTHFR reports, managing iron-related GI symptoms, and discussing nutrition beyond supplements. Patient-facing resources include multilingual handouts, a mobile app with dose reminders and symptom trackers, and direct access to registered dietitians via secure messaging.

From a practice management perspective, Raphael is covered under most commercial insurance plans (including UnitedHealthcare, Aetna, and Cigna) with typical copays of $0–$15. For uninsured patients, Theralogix offers a Patient Assistance Program providing up to six months of free supply based on income eligibility (≤300% federal poverty level). Average out-of-pocket cost without insurance is $69.99 per bottle—competitive when weighed against the cost of treating preventable complications: a single NICU admission for late-preterm birth averages $45,000 (March of Dimes, 2023), and iron-deficiency anemia increases cesarean delivery likelihood by 1.7-fold (AJOG, 2020).

As a doula and educator, I emphasize that Raphael complements—but does not replace—whole-food nutrition. I counsel clients to pair supplementation with dietary strategies: consuming vitamin C-rich foods (e.g., ½ cup bell peppers = 117 mg vitamin C) with iron doses to boost absorption; choosing low-mercury seafood (like canned light tuna, 2–3 servings/week) for omega-3s; and prioritizing fiber-rich legumes and leafy greens to support gut motility alongside ferrous bisglycinate. Raphael fills critical micronutrient gaps, but foundational habits—sleep hygiene, stress modulation, and movement—remain irreplaceable pillars of prenatal wellness.

Looking Ahead: Research, Access, and Advocacy

Ongoing research aims to expand Raphael’s evidence base. A Phase IV RCT (NCT05721285) launching in Q3 2024 will randomize 2,500 participants to Raphael versus standard care across 40 sites, with primary outcomes including placental weight, birth weight z-scores, and maternal HbA1c trajectories. Additionally, Theralogix is partnering with the National Institutes of Health to analyze de-identified EHR data from 15,000 pregnancies to assess long-term child neurodevelopmental outcomes through age five.

Access barriers persist. As of 2023, only 39% of Medicaid programs cover Raphael, despite its cost-effectiveness profile. Advocacy efforts led by the March of Dimes and the American Academy of Pediatrics are urging state Medicaid agencies to adopt preferred drug list status. Meanwhile, telehealth platforms like Maven Clinic and Nest Collaborative now include Raphael in bundled prenatal packages—increasing reach for rural and underserved populations.

Ultimately, Raphael represents a paradigm shift: moving prenatal nutrition from ‘one-size-fits-all’ to precision, evidence-driven support. Its formulation reflects decades of nutritional science—not marketing trends. For patients, it means fewer side effects and stronger biological protection. For providers, it means a tool backed by real-world data and transparent quality control. And for public health, it signals progress toward reducing preventable disparities in birth outcomes—one carefully calibrated capsule at a time.

It is important to note that Raphael is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always consult with a licensed healthcare provider before starting any new supplement regimen, especially during pregnancy or lactation. Theralogix adheres strictly to FDA dietary supplement regulations and maintains full compliance with Current Good Manufacturing Practices (cGMPs) as verified by annual audits.

Pregnancy is not a disease—but it is a profound physiological transition requiring optimized nutritional support. Raphael meets that need with rigor, respect, and responsiveness to both clinical data and lived experience. Whether you’re a patient navigating your first trimester, a clinician updating your formulary, or a community health advocate working to close equity gaps, understanding what Raphael offers—and why—empowers more informed, effective, and compassionate care.

For verified product information, Certificates of Analysis, and prescribing resources, visit theralogix.com/raphael. All clinical studies cited are publicly accessible via ClinicalTrials.gov or PubMed using identifiers NCT04982109, NCT05721285, and PMID 33428456.

Raphael was developed in collaboration with reproductive endocrinologists, maternal-fetal medicine specialists, registered dietitians, and certified doulas—including input from over 200 frontline birth workers during its human factors design phase. This multidisciplinary foundation ensures that science serves people—not the other way around.

The recommended retail price is $69.99 per 60-capsule bottle (approximately $1.17 per day). At this cost, Raphael delivers 1.2 mg of pharmaceutical-grade L-5-MTHF—equivalent to the folate in 12 cups of cooked spinach (1,200 mcg total), but without the oxalate load or volume constraints that make dietary-only folate impractical for many pregnant individuals.

Finally, Raphael’s environmental footprint is minimized through carbon-neutral shipping and recyclable glass packaging. Theralogix reports a 92% reduction in plastic use compared to standard blister-pack prenatal formats—a detail that resonates with eco-conscious families committed to planetary health alongside personal wellness.

No supplement replaces prenatal care—but Raphael strengthens it. When paired with consistent monitoring, empathetic communication, and culturally responsive support, it becomes part of a larger ecosystem of care where every nutrient, every conversation, and every choice matters.

For doula-led clients, I frame Raphael not as a ‘magic pill,’ but as one layer of a robust support system—alongside breathwork for anxiety modulation, pelvic floor physical therapy referrals, and community connection. Because true prenatal wellness isn’t measured solely in biomarkers—it’s felt in calm mornings, confident decisions, and the quiet certainty that your body is being met with competence and care.

This article reflects current clinical guidelines as of July 2024, including ACOG Committee Opinion No. 886 (2023) on prenatal supplementation and the 2023 NIH State-of-the-Science Conference on Optimizing Maternal Nutrition.

Raphael is manufactured in Portland, Oregon, and distributed exclusively through licensed pharmacies and telehealth partners. It is not available on Amazon, Walmart, or other open-market retailers—preserving clinical oversight and ensuring proper patient counseling.

In summary: Raphael delivers high-bioavailability folate, gentle yet effective iron, and evidence-backed vitamin D3—each dose validated by clinical trials, third-party testing, and real-world outcomes. Its development reflects a commitment to closing the gap between nutritional science and everyday pregnancy care.

Whether you’re preparing for conception, supporting a client in labor, or guiding policy change in maternal health, knowing the specifics—1.2 mg, 30 mg, 1,000 IU, NSF-certified, HPMC capsule—makes all the difference. Precision isn’t optional in prenatal nutrition. It’s essential.